Intellia Therapeutics (NTLA) Capital Expenditures (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Capital Expenditures data on file, last reported at $79000.0 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $79000.0, down 3.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $29000.0 (up 101.57% YoY), and the FY2025 annual result was $32000.0, down 94.45% from the prior year.
• Capital Expenditures advanced to $79000.0 in Q1 2026 per NTLA's latest filing, from $32000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $4.3 million in Q2 2023 and troughed at -$6.6 million in Q3 2023.
• A 5-year average of $985687.5 and a median of $885000.0 in 2022 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 312.99% in 2022, then sank 15529.63% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $3.9 million in 2022, then sank by 100.69% to -$27000.0 in 2023, then slumped by 15529.63% to -$4.2 million in 2024, then soared by 100.76% to $32000.0 in 2025, then jumped by 146.88% to $79000.0 in 2026.
• Business Quant data shows NTLA's Capital Expenditures at $79000.0 in Q1 2026, $32000.0 in Q4 2025, and -$82000.0 in Q2 2025.